Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong product development and market strategy, especially with the PALSONIFY launch and its appeal to both patients and prescribers. The Q&A section indicates effective execution and positive reception, despite minor uncertainties in payer approval timing. Financial guidance shows controlled cash usage, and the company is well-capitalized. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
Key Financial Performance
Revenue $0.1 million in revenue from licensing agreement with Japanese partner, SKK. No revenue recognized from PALSONIFY launch in Q3 due to timing of approval close to the end of the quarter. Revenue from PALSONIFY will be recognized in Q4.
Research and Development Expenses $90.5 million in Q3 2025, up from $80.3 million in Q2 2025. Increase due to continued investment in clinical programs, including start-up costs for late-stage clinical trials and advancement of CRN09682.
Selling, General and Administrative Expenses $52.3 million in Q3 2025, up from $49.8 million in Q2 2025. Increase reflects investments in PALSONIFY's launch, including onboarding and deploying field force, strategic marketing initiatives, and corporate function growth.
Cash Used in Operations $110.7 million in Q3 2025, slightly higher than anticipated due to timing of payables. Reflects clinical development and launch preparation activities.
Cash Position $1.1 billion in cash, cash equivalents, and investments as of the end of Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PALSONIFY launch: The launch of PALSONIFY, a treatment for acromegaly, is progressing well. It is being positioned as the first-line treatment for acromegaly, with significant progress made in the first 31 days post-approval. Patients are transitioning from injectable therapies to PALSONIFY, and newly diagnosed patients are also starting with it. The company is focusing on activating pituitary centers and engaging community endocrinologists. Early payer feedback is positive, with prior authorizations being straightforward and some approvals for up to 12-month supplies.
Pipeline development: The company is advancing its pipeline with late-stage programs for carcinoid syndrome and congenital adrenal hyperplasia (CAH). Phase 3 trials for these indications are underway, and initial data from these programs is expected in 2026. The company is also working on expanding its clinical pipeline and discovery activities.
Acromegaly market expansion: The company is targeting three phases to expand the acromegaly market: switching patients from injectable therapies, re-engaging previously diagnosed patients who discontinued therapy, and improving diagnosis rates. Efforts include raising awareness and engaging healthcare providers.
Financial performance: The company reported $0.1 million in revenue from licensing agreements in Q3 2025. No revenue from PALSONIFY was recognized in Q3 due to timing, but revenue has been recognized in Q4. R&D expenses were $90.5 million, and SG&A expenses were $52.3 million. The company has $1.1 billion in cash and expects to fund operations into 2029.
Operational efficiencies: The company is leveraging its field team, including sales representatives, medical science liaisons, and nurse educators, to support the launch of PALSONIFY. It is also engaging with payers to streamline prior authorizations and reimbursement processes.
Strategic shifts in pipeline focus: The company is delaying timelines for its TSH candidate for Graves' disease and SST3 agonist program for ADPKD due to identified weaknesses and follow-up studies. It will no longer provide regular updates on preclinical programs until they reach Phase 1.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: Forward-looking statements are subject to risks and uncertainties as disclosed in SEC filings. Delays in IND timelines for Graves' disease and SST3 agonist program for ADPKD due to identified weaknesses in lead candidates.
Market and Commercialization Risks: Challenges in establishing PALSONIFY as the first-line treatment for acromegaly, including competition from existing therapies and the need to activate previously diagnosed and lost-to-follow-up patients. Full formulary coverage for PALSONIFY is expected to take 6-9 months, which could delay broader adoption.
Operational Risks: Increased R&D and SG&A expenses due to clinical programs and commercialization efforts. Cash used in operations was higher than anticipated due to timing of payables.
Clinical Development Risks: Delays in preclinical programs and IND-enabling studies for new candidates. High bar set for Phase 3 CALM-CAH trial with a novel primary endpoint, which could pose challenges in achieving desired outcomes.
Economic and Financial Risks: High cash burn rate with $110.7 million used in operations during the quarter. Dependence on existing cash reserves to fund operations into 2029, with no immediate revenue from PALSONIFY in Q3 due to timing of approval.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company expects to recognize revenue from PALSONIFY starting in the fourth quarter of 2025, following its launch late in the third quarter.
Cash Guidance: The company maintains its guidance for net cash used in operations in 2025 to be between $340 million and $370 million. Existing cash and investments are expected to fund operations into 2029.
PALSONIFY Launch Strategy: The company is in Phase 1 of a 3-phase strategy to establish PALSONIFY as the first-line treatment for acromegaly. Phase 1 focuses on switching patients from injectable therapies to PALSONIFY and targeting newly diagnosed patients. Phase 2 will aim to bring previously diagnosed patients back to care, and Phase 3 will focus on improving diagnosis rates for acromegaly.
Pipeline Development: The company plans to advance its late-stage clinical programs, including Phase 3 trials for carcinoid syndrome and congenital adrenal hyperplasia (CAH). It also expects to expand its clinical pipeline in 2026 and beyond.
Clinical Data Readouts: Key data readouts are expected in early 2026, including results from the CALM-CAH Phase 3 trial, BALANCE-CAH Phase 2 pediatric study, and CAREFNDR Phase 3 trial in carcinoid syndrome.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you tell us what the evidence is for somatostatin receptor ligands in this setting? Will you ever want to conduct survival studies with paltusotine alone?
A:Somatostatin receptor ligands are known to slow the growth of neuroendocrine tumors, as proven in the CLARINET study with lanreotide. Mechanistically, paltusotine is expected to have a similar effect. Progression-free survival (PFS) is used as a surrogate for survival outcomes in neuroendocrine tumors due to their slow growth. Current data from Phase 2 open-label extension patients shows PFS comparable to long-term trials, and more data will come from Phase 3 cohorts.
Q:What model did you see the tox signals in the Graves' disease candidate? Was it an on-target toxicity or hitting an unexpected receptor?
A:The toxicity signals were idiosyncratic and not related to on-target activity. The mechanistic biology of the TSH receptor is well understood, and this was not a concern.
Q:How many prescribers has the sales force called on? What is the concentration of the 10,000 acromegaly patients at these centers? What was the initial perception of PALSONIFY, and how many have converted to prescribers?
A:The sales force has called on over 95% of top priority prescribers, which includes approximately 110 prescribers. 70% of prescriptions are coming from community prescribers and 30% from PTC centers. The response has been positive, with healthcare professionals appreciating the simple and effective message of the treatment. Initial prescriptions are coming from both community and PTC centers.
Q:Why are some PTC centers lagging behind in prescribing PALSONIFY compared to community practices?
A:Community practices are more nimble and willing to reach out to patients directly, while PTC centers often wait for patients' next appointments. Administrative tasks like activating electronic medical systems and pharmacies at centers also take time, but these issues are being resolved.
Q:How are you thinking about providing free drug while getting reimbursement? What are your expectations for the CAH open-label data in early 2026?
A:The market access team partners with specialty pharmacies to file prior authorizations and ensure claims are reimbursed. If there are challenges, the Quick Start program is used to provide the drug while resolving issues. For CAH open-label data, early 2026 will provide data from Cohort 4 patients and some from Cohorts 1-3, offering insights into real-world settings and the ability to reduce glucocorticoids.
Q:What is the awareness within the acromegaly community about PALSONIFY? Are prescriptions driven by clinicians or patients?
A:Both clinicians and patients are driving prescriptions. Some patients are asking their doctors for PALSONIFY, while others are being informed by their physicians. The experienced team is working to ensure both audiences are informed.
Q:What is interesting prescribers and patients about PALSONIFY?
A:Prescribers are intrigued by the fast onset of action and reliable disease control, making it a first treatment choice for some patients. Patients appreciate the convenience of an oral therapy and the efficacy shown in clinical trials. Examples include patients with specific needs like frequent travel or avoiding painful injections.
Q:Has the timing of benefit verification for the Quick Start program met expectations? When will there be clear visibility into prescribing trends?
A:Benefit verification is happening in the background while patients are on the Quick Start program. The average time for rare diseases is 57 days, and the team aims to be below that. Prescribing trends will be updated further as the quarter progresses.
Q:What has been going well in the PALSONIFY launch, and where can improvements be made?
A:The sales, marketing, and market access teams are executing well, with strong CRM activation and omnichannel strategies. Advisory boards are providing valuable feedback. Improvements focus on creating urgency among physicians to prescribe earlier rather than waiting for routine appointments.
Q:Are most patients in the PALSONIFY launch from commercial, Medicare, or Medicaid segments?
A:There is a mix of commercial, Medicare, and Medicaid patients, with claims approved across all three segments. The majority are commercial, following market trends.
Q:What is the turnaround time for payers to approve PALSONIFY?
A:It is too early in the launch to calculate an average turnaround time for payer approvals.
Q:What is the plan to reach additional treatment-naive patients, and what will drive long-term growth?
A:Efforts focus on newly diagnosed patients, those who discontinued therapy, and undiagnosed patients. Awareness campaigns and the drug's profile are expected to bring patients back to care and improve diagnosis rates.
Q:How do you expect to position PALSONIFY as a first-line therapy with generics on the market?
A:PALSONIFY's fast onset of action and reliable disease control make it a better option for newly diagnosed patients. Generics lack the support services and benefits offered by PALSONIFY.
Q:What should we focus on in the Cohort 4 data for Atumelnant?
A:Cohort 4 data will provide directionality but is based on small patient numbers. It will offer insights into steroid reductions and real-world settings but should not be used for power calculations.
Q:How does the traction in the PALSONIFY launch compare to market research?
A:The traction aligns with expectations, with no significant pushback from prescribers. The team is building momentum and addressing system inertia.
Q:Are there different dynamics for naive patients compared to switch patients?
A:The dynamics are similar, with claims being reimbursed or processed through the Quick Start program.
Q:How many patients in the open-label extension are transitioning to commercial supply?
A:All 22 patients in the open-label extension are transitioning to commercial supply, with most expected to complete the process by the end of the year.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the turnaround time for payers to approve PALSONIFY, stating it was too early in the launch to calculate an average. Additionally, they did not provide exact timing for the preliminary Phase 2 data for Atumelnant in pediatric patients, only mentioning that it would come in phases.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CAH trial
CALM CAH
HCP
Isabel
PALSONIFY acromegaly
People
Phase study
Toby
ability androgen
acromegaly awareness
candidate drug
care reason
choice patient
cohort week
commercialization PALSONIFY
community setting
day approval
depot
effort patient
field force
field team
freedom
goal PALSONIFY
lab
label
launch PALSONIFY
launch field
marketing
number patient
patient PALSONIFY
phase
physician
prescribers
process
share
start
stock
story
symptom control
therapy PALSONIFY
timing
CRNX Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call shows strong revenue growth and improved net loss, but also highlights increased R&D expenses and a recent equity offering, which can dilute share value. The lack of strategic updates or risk discussions, coupled with unclear management responses in the Q&A, suggests uncertainty. Given the market cap, these mixed signals balance out to a neutral sentiment, indicating a likely stock price fluctuation within -2% to 2% over the next two weeks.
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call highlights a strong revenue growth forecast (15%-20%) and improved operating margins, alongside successful product launches and market expansion in endocrinology. Despite a net loss, cost-cutting measures have improved financial health. The absence of explicit risks further supports a positive outlook. With a market cap of $3.4 billion, the positive guidance and strategic initiatives are likely to result in a moderate stock price increase of 2% to 8%.
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call highlights strong product development and market strategy, especially with the PALSONIFY launch and its appeal to both patients and prescribers. The Q&A section indicates effective execution and positive reception, despite minor uncertainties in payer approval timing. Financial guidance shows controlled cash usage, and the company is well-capitalized. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
CRNX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
